Xeris Biopharma Holdings, Inc. provided revenue guidance for the full year 2023. For the year, the company tightens its 2023 guidance by raising the low end of the total revenue range to $145 million - $165 million from $135 to $165 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | +7.39% | -0.26% | -19.57% |
05-09 | Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.57% | 280M | |
+29.98% | 682B | |
+30.34% | 586B | |
-3.52% | 364B | |
+18.59% | 327B | |
+4.07% | 285B | |
+16.21% | 240B | |
+9.66% | 209B | |
-6.83% | 203B | |
+7.09% | 165B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2023